乳腺超声造影预测HER-2阳性乳腺癌曲妥珠单抗化疗敏感性的价值  

Value of breast contrast-enhanced ultrasound in predicting the chemosensitivity of patients with HER2-positive breast cancer to trastuzumab

作　　者：袁莹莹 蔡艳[1] 周晓霞 郑国连[1] YUAN Ying-ying;CAI Yan;ZHOU Xiao-xia;ZHENG Guo-lian(Department of Ultrasound Medicine,Zhanjiang Central People's Hospital,Zhanjiang 524000,Guangdong,CHINA)

机构地区：[1]湛江中心人民医院超声医学科,广东湛江524000

出　　处：《海南医学》2024年第18期2676-2679,共4页Hainan Medical Journal

摘　　要：目的研究乳腺超声造影预测人类表皮生长因子受体2(HER-2)阳性乳腺癌患者对曲妥珠单抗化疗敏感性的价值。方法回顾性分析2023月1月至2024年1月湛江中心人民医院诊疗的187例HER-2阳性乳腺癌患者的临床和影像资料,所有患者均接受曲妥珠单抗治疗,按照治疗第1个周期(3周)的疗效分为不敏感组122例和敏感组65例,所有患者在治疗第1个周期结束后均接受乳腺超声造影检查,比较两组患者治疗第1个周期结束后的乳腺超声造影表现。结果治疗敏感组患者病灶的最大径为(2.91±0.33)cm,明显小于不敏感组患者的(4.67±0.75)cm,差异有统计学意义(P<0.05);治疗不敏感组患者的高增强率、快进增强模式、增强后肿物不清晰、增强后肿块形态不规则、周围有穿行血管的占比分别为100.00%、100.00%、79.51%、86.07%、100.00%,明显高于治疗敏感组患者的83.08%、60.00%、63.08%、69.23%、80.00%,差异均有统计学意义(P<0.05)。结论乳腺超声造影在预测HER-2阳性乳腺癌曲妥珠单抗治疗敏感性中有一定价值,可指导临床治疗。Objective To study the value of breast contrastenhanced ultrasound in predicting the chemosensitivity of patients with human epidermal growth factor receptor HER2 positive breast cancer to trastuzumab.Methods The clinical and imaging data of 187 patients with HER2 positive breast cancer treated in Zhanjiang Central People's Hospital from January 2023 to January 2024 were retrospectively analyzed.All the patients were treated with trastuzumab,and they were divided into insensitive group(122 cases)and sensitive group(65 cases)according to the curative effect of the first cycle(three weeks)of treatment.All the patients were examined by breast contrastenhanced ultrasound after the first cycle of treatment,and the performance of contrastenhanced ultrasound was compared between the two groups.Results The maximum diameter of the lesion in the sensitive group was(2.91±0.33)cm,which was significantly smaller than(4.67±0.75)cm in the insensitive group(P<0.05).The proportions of high enhancement rate,fastforward enhancement mode,unclear mass after enhancement,irregular mass shape after enhancement,and surrounding blood vessels in the insensitive group were 100.00%,100.00%,79.51%,86.07%,and 100.00%,which were significantly higher than 83.08%,60.00%,63.08%,69.23%,and 80.00%of the sensitive group(P<0.05).Conclusion Breast contrastenhanced ultrasound has certain value in predicting the chemosensitivity to trastuzumab in patients with HER2positive breast cancer.

关 键 词：乳腺癌 人类表皮生长因子受体2阳性 曲妥珠单抗 乳腺超声造影 化疗敏感性 

分 类 号：R737.9[医药卫生—肿瘤]